Agennix AG / Agennix AG Schedules Conference Call on May 6, 2010 to Discuss First Quarter 2010 Financial Results processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. 

Martinsried/Munich  (Germany), Princeton,  NJ and  Houston, TX, April 30, 2010 -
Agennix AG (Frankfurt Stock Exchange: AGX) today announced that the Company will
hold  a conference call  to discuss financial  results for the  first quarter of
2010 and  to  provide  a  business  update.  The  results  will  be published on
Thursday, May 6, 2010 in advance of the conference call.
The  conference  call,  which  will  be  conducted  in  English, will be held on
Thursday, May 6, 2010 at 9 AM ET/ 3 PM CET.
A  live webcast will be available on  the Agennix Web site at www.agennix.com. A
replay will be available via the Web site following the live event.
Dial-in numbers for the call are as follows:

Participants from Europe:0049 (0)69 667775756
0044 (0)20 3003 2666
Participants from the U.S.:1-646-843-4608
Please dial in 10 minutes before the beginning of the meeting.

About Agennix
Agennix  AG is  a publicly  traded biopharmaceutical  company that is developing
novel  therapies in areas of major unmet  medical need to improve the length and
quality  of life of seriously ill  patients. The Company's most advanced program
is  talactoferrin, an  oral targeted  therapy that  has demonstrated activity in
randomized,  double-blind, placebo-controlled Phase  2 studies in non-small cell
lung cancer, as well as in severe sepsis. Talactoferrin is currently in Phase 3
clinical  trials  in  non-small  cell  lung  cancer.  Other clinical development
programs  include  RGB-286638,  a  multi-targeted  kinase  inhibitor in Phase 1
testing; the oral platinum-based compound satraplatin; and a topical gel form of
talactoferrin  for  diabetic  foot  ulcers.  Agennix's  registered  seat  is  in
Heidelberg,    Germany.    The   Company   has   three   sites   of   operation:
Martinsried/Munich,  Germany;  Princeton,  New  Jersey  and  Houston, Texas. For
additional information, please visit the Agennix Web site at www.agennix.com.
This  press  release  contains  forward-looking  statements,  which  express the
current  beliefs  and  expectations  of  the  management  of  Agennix  AG.  Such
statements  are  based  on  current  expectations  and  are subject to risks and
uncertainties,  many of  which are  beyond our  control, that could cause future
results,  performance or achievements to  differ significantly from the results,
performance  or  achievements  expressed  or  implied  by  such  forward-looking
statements.  Actual results  could differ  materially depending  on a  number of
factors,   and  we  caution  investors  not  to  place  undue  reliance  on  the
forward-looking  statements  contained  in  this  press release. Forward-looking
statements  speak  only  as  of  the  date  on  which  they are made and Agennix
undertakes no obligation to update these forward-looking statements, even if new
information becomes available in the future.


For further information, please contact:


Agennix
AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com


In the U.S.: Laurie
Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884

laurie.doyle@agennix.com



Additional media contacts for Europe:
MC Services
AG
Phone: +49 (0) 89 210 228 0

Raimund
Gabriel
raimund.gabriel@mc-services.eu


Hilda
Juhasz
hilda.juhasz@mc-services.eu



Additional investor contact for Europe:
Trout International
LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com 



[HUG#1410480]



 --- End of Message --- 

Agennix AG
Im Neuenheimer Feld 515 Heidelberg Germany

ISIN: DE000A1A6XX4;
Listed: Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;